



**UNIVERSITY OF LEEDS**

This is a repository copy of *Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/126281/>

Version: Accepted Version

---

**Article:**

Calvert, M, Kyte, D, Mercieca-Bebber, R et al. (4 more authors) (2018) Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. *JAMA - Journal of the American Medical Association*, 319 (5). pp. 483-494. ISSN 0098-7484

<https://doi.org/10.1001/jama.2017.21903>

---

© 2018, American Medical Association. This is an author produced version of a paper published in *JAMA - Journal of the American Medical Association*. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

1 **Title:** Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-  
2 PRO Extension

3

4 **Authorship:**

5 Melanie Calvert, PhD; Derek Kyte, PhD; Rebecca Mercieca-Bebber, PhD; Anita Slade, PhD; An-Wen  
6 Chan, MD, DPhil; Madeleine T King, PhD; and the SPIRIT-PRO Group.

7

8 **Author Affiliations:**

9 Centre for Patient-Reported Outcomes Research, Institute of Applied Health Research, University of  
10 Birmingham, UK (Prof Calvert, Dr Kyte, Dr Slade); Sydney Medical School, Faculty of Medicine and  
11 School of Psychology, Faculty of Science, University of Sydney, Australia (Prof King, Dr Mercieca-  
12 Bebber); Women's College Research Institute and Dept of Medicine, University of Toronto (Prof  
13 Chan).

14

15 **Corresponding author:** Prof Melanie Calvert, Centre for Patient Reported Outcomes Research,  
16 Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, UK B15 2TT  
17 [m.calvert@bham.ac.uk](mailto:m.calvert@bham.ac.uk) +44(0)121 4148595

18

19

20 **Key Points:**

21 **Question:** What information should be included in a clinical trial protocol when a patient-reported  
22 outcome (PRO) is a primary or key secondary outcome?

23 **Findings:** Following an international consensus development process using the Enhancing QUALity  
24 and Transparency Of health Research (EQUATOR) methodology, sixteen PRO specific items are  
25 recommended for inclusion in clinical trial protocols.

26 **Meaning:** Inclusion of these items in clinical trial protocols may help improve the quality of PRO data.

27

28 **Revision:** 18 December 2017

29 **Word Count:** 3941

30 **ABSTRACT (338/350 words)**

31

32 **Importance**

33 Patient-reported outcome (PRO) data from clinical trials can provide valuable evidence to inform  
34 shared-decision making, labelling claims, clinical guidelines, and health policy; however, the PRO  
35 content of clinical trial protocols is often suboptimal. The SPIRIT (Standard Protocol Items:  
36 Recommendations for Interventional Trials) Statement was published in 2013 and aims to improve the  
37 completeness of trial protocols by providing evidence-based recommendations for the minimum set of  
38 items to be addressed, but does not provide PRO-specific guidance.

39

40 **Objective**

41 To develop international, consensus-based, PRO-specific protocol guidance: the SPIRIT-PRO  
42 extension.

43

44 **Design, Setting, and Participants**

45 The SPIRIT-PRO Extension was developed following the Enhancing QUALity and Transparency Of  
46 health Research (EQUATOR) Network's methodological framework for guideline development. This  
47 included: (i) a systematic review of existing PRO-specific protocol guidance to generate a list of  
48 candidate PRO-specific protocol items (published 2014); (ii) refinements to the list and removal of  
49 duplicate items by the International Society for Quality of Life Research (ISOQOL) PROtocol Checklist  
50 Taskforce; (iii) an international stakeholder survey of: clinical trial research personnel, PRO  
51 methodologists, health economists, psychometricians, patient advocates, funders, industry  
52 representatives, journal editors, policy makers, ethicists and researchers responsible for evidence  
53 synthesis (distributed by 38 international partner organizations, October 2016); (iv) an international  
54 Delphi exercise (n=137 invited; October 2016 to February 2017)and consensus meeting (n=30  
55 invited; May 2017). Prior to voting, consensus meeting participants were informed of the results of the  
56 Delphi exercise and given data from structured reviews evaluating the PRO protocol content of three  
57 defined samples of trial protocols.

58

59 **Results**

60 The systematic review identified 162 PRO-specific protocol recommendations from 54 sources. The  
61 ISOQOL Taskforce (n=21) reduced this to 56 items, which were considered by 138 international  
62 stakeholders and 99 Delphi panelists. The final wording of the SPIRIT-PRO Extension was agreed at  
63 a consensus meeting (n=29 participants) and reviewed by external stakeholders during a consultation  
64 period. Eleven extensions and five elaborations to the SPIRIT 2013 checklist are recommended for  
65 inclusion in clinical trial protocols where PROs are a primary or key secondary outcome. Extension  
66 items focused on PRO specific issues relating to the: trial rationale, objectives, eligibility criteria,  
67 concepts used to evaluate the intervention, timepoints for assessment, PRO instrument selection and  
68 measurement properties, data collection plan, translation to other languages, proxy completion,  
69 strategies to minimise missing data and whether PRO data will be monitored during the study to  
70 inform clinical care.

71

## 72 **Conclusions and relevance**

73 These guidelines provide recommendations for items that should be addressed and included in  
74 clinical trial protocols in which PROs are a primary or key secondary outcome. Improved design of  
75 clinical trials including PROs could help ensure high-quality data that may inform patient-centered  
76 care.

77

78

79

80

81

82

83

84

85 **INTRODUCTION**

86 Clinical trial protocols are essential documents that describe the study design and conduct. A  
87 protocol should provide sufficient detail to enable funders, reviewers and ethics committees to  
88 appraise the trial's scientific, methodological and ethical rigor and for the research team to deliver a  
89 high quality study.<sup>1,2</sup> Although they serve as the foundation for study planning, conduct, reporting, and  
90 appraisal, trial protocols vary greatly in content and quality.<sup>1,2</sup> To address this issue, the SPIRIT  
91 (Standard Protocol Items: Recommendations for Interventional Trials) Statement was published in  
92 2013.<sup>1,2</sup> SPIRIT provides an evidence-based list of items recommended for inclusion in trial protocols.  
93 It does not, however, provide specific guidance on protocol content relating to patient-reported  
94 outcomes (PROs), such as health-related quality of life (HRQOL) or patient-reported symptoms.

95

96 The importance of PROs has been recognized by major international health policy and regulatory  
97 authorities and patients.<sup>3-5</sup> PRO trial results, if captured in a scientifically rigorous way, may inform  
98 clinical decision-making<sup>6</sup>, pharmaceutical labelling claims<sup>4-5</sup>, product reimbursement and influence  
99 healthcare policy.<sup>6</sup> Despite this, the quality of PRO content in many protocols is often suboptimal,  
100 regardless of the degree of adherence to SPIRIT.<sup>7-9</sup> Because PROs are intrinsically subjective and  
101 require completion by patients within a specific time-frame, they present a range of scientific and  
102 logistical challenges for researchers and data collection staff.<sup>10-12</sup> Comprehensive planning and  
103 instruction in the protocol can mitigate many PRO-specific issues through trial conduct, and  
104 subsequent analysis and reporting. Protocol developers, particularly those not familiar with PRO  
105 methodology, may benefit from explanation of PRO-specific aspects to facilitate improvements in  
106 content.

107

108 The aim of this international project was to develop an evidence-based extension of the SPIRIT 2013  
109 statement, identifying additional PRO items recommended for inclusion in clinical trial protocols  
110 (extensions) and to elaborate on the existing SPIRIT 2013 statement specifically as applied to PROs  
111 (elaborations).<sup>13</sup> This article describes the methods used to gain consensus on each additional  
112 SPIRIT-PRO extension/elaboration, provides a brief explanatory rationale, and includes PRO specific  
113 items that may be included in supplemental trial documents.

114

115

116 **SPIRIT-PRO DEVELOPMENT METHODS**

117 The SPIRIT-PRO Extension was developed according to the Enhancing QUALity and Transparency Of  
118 health Research (EQUATOR) Network's methodological framework for guideline development  
119 (eFigure 1 in Supplement 1).<sup>14</sup> This included: a systematic review of existing PRO-specific protocol  
120 guidance<sup>15</sup>; an international stakeholder survey; Delphi exercise and consensus meeting; followed by  
121 consultation on the final SPIRIT-PRO Extension.<sup>14</sup> The systematic review comprised a search of  
122 MEDLINE, EMBASE, CINHAL and Cochrane Library databases (inception to February 2013) using  
123 the key words 'Patient-Reported Outcomes' or 'Health-Related Quality of Life' in combination with  
124 'Guidance', 'Guidelines' or 'Checklist'. Further guidance documents were identified via Google,  
125 Google scholar, requests to members of the UK Clinical Research Collaboration registered clinical  
126 trials units, international experts and through citation and reference searches of included articles.  
127 Papers were deemed eligible if they contained guidance and/or a checklist on PRO related trial  
128 protocol content.<sup>15</sup>

129 eFigure 1 summarizes the methods and participants involved in the development of SPIRIT-PRO, the  
130 numbers of candidate items considered at each step, and the flow towards the final set of items  
131 included in SPIRIT PRO. eTable 1 in Supplement 1 outlines the participant characteristics. Patient  
132 partners contributed to the co-design of the research, grant application, have provided input  
133 throughout the study and are coauthors.

134

135 **Ethical Review of Study**

136 Ethical approval was provided by The University of Birmingham Ethical Review Board (Reference:  
137 ERN\_16-0819). Participant information was provided to potential participants prior to survey  
138 completion and in advance of the consensus meeting. Survey participants provided electronic  
139 informed consent and written consent was provided by the consensus meeting participants.

140

141 **Systematic review of existing PRO-specific protocol guidance and development of the Delphi  
142 and Stakeholder Survey**

143 Our systematic review of existing PRO protocol guidance identified 162 PRO-specific protocol  
144 recommendations from 54 sources<sup>15</sup>. The International Society for Quality of Life Research (ISOQOL)  
145 PROtocol Checklist Taskforce comprising international experts in PROs research and clinical trials

146 (eTable 1 and Acknowledgments, Supplement 1) reduced this list to 56 candidate items by removing  
147 or merging duplicate items, meaning 56 items were included in the subsequent identical Stakeholder  
148 and Delphi surveys. Survey participants were asked to rate the importance of including each of the 56  
149 candidate items in the final SPIRIT-PRO Extension using a 9-point scale: 'not important' (1-3),  
150 'important but not critical' (4-6) and 'critical' (7-9). Respondents provided separate ratings according to  
151 whether a PRO was included as a primary versus secondary outcome in a trial.

152

### 153 **International stakeholder survey**

154 In 2016, 38 international partner organizations (detailed in Supplement 1) invited their members with  
155 relevant expertise to complete an online survey. From these organizations, a total 138 participants  
156 provided anonymized survey results which informed round 2 of the Delphi panel exercise.

157

### 158 **International Delphi exercise**

159 In parallel with the international stakeholder survey, key experts (n=114) from the ISOQOL PROtocol  
160 Checklist Taskforce, international partner organizations and other experts known or recommended to  
161 the SPIRIT-PRO Executive were invited to join an international, multidisciplinary expert Delphi Panel.  
162 Delphi panelists were advised not to complete the stakeholder survey to avoid double counting of  
163 results. Delphi panelists (n=99) completed 2 rounds of online surveys and results informed the  
164 subsequent international consensus meeting. Data collected from the stakeholder and round 1 Delphi  
165 surveys were anonymized and the item-level results were provided to the Delphi panel for  
166 consideration prior to voting in Delphi round 2. Further details and the results of the Delphi and  
167 stakeholder surveys are available on the study website.<sup>16</sup>

168

### 169 **Consensus meeting**

170 Using the Stakeholder and Delphi survey results, the SPIRIT-PRO Operations Team (MC, DK, RMB,  
171 AS, MK) mapped the 56 candidate SPIRIT-PRO items to corresponding SPIRIT-2013 items, revising  
172 wording as needed to address stakeholder/Delphi panelist comments. For each candidate SPIRIT-  
173 PRO item, the Operations Team presented the consensus meeting delegates with recommendations  
174 for SPIRIT 'elaborations' and 'extensions' (see Box for definitions ) based on a decision tree (eFigure  
175 2 in Supplement 1), which incorporated information drawn from the Delphi survey and three separate

176 reviews of PRO protocol content (n= 207 protocols): protocols from the UK National Institute for  
177 Health Research (NIHR) Health Technology Assessment (HTA) programme<sup>7</sup>; cancer trial protocols  
178 from the NIHR<sup>8</sup> and international ovarian cancer protocols<sup>9</sup>. Twenty-nine participants purposively  
179 sampled from the Delphi panel attended the two-day consensus meeting hosted by the University of  
180 Birmingham, England, in May 2017 (eTable 1). The meeting was designed to seek consensus on the  
181 content of the SPIRIT-PRO Extension. Meeting participants were invited to consider the focus of the  
182 guidance and agreed that it should apply to trials where PROs are a primary or key secondary  
183 outcome (as defined in Glossary). Delegates anonymously voted using Turning point© (v5.1,  
184 2012)/Responseware© software to either: include the candidate item as recommended; exclude the  
185 item; or initiate further discussion. Key research evidence (Round 2 Delphi survey results and  
186 systematic review data) presented to meeting participants is provided in Supplement 2. Consensus  
187 meeting participants were also invited to review Delphi results for recommendation on where to  
188 include each of the candidate items in addition to, or instead of, the trial protocol (eg,  
189 guidance/training for trial staff, information/guidance for study participants, or the statistical analysis  
190 plan (SAP).

191

## 192 **Final consultation**

193 Following the consensus meeting, attendees commented on wording and agreed on the penultimate  
194 SPIRIT-PRO Extension content. Broader feedback on the final guidance was sought from our Delphi  
195 panel and international partners during a three week consultation period. Final edits in response to  
196 feedback were made by the Operations Team and agreed by the SPIRIT-PRO Group.

197

## 198 **RESULTS**

199

### 200 **SPIRIT-PRO Checklist Items and Explanation**

201 The final SPIRIT-PRO Extension recommends that, in conjunction with existing SPIRIT 2013 items,  
202 16 items should be routinely addressed in all clinical trial protocols where PROs are a primary or key  
203 secondary outcome (11 extensions; 5 elaborations). Further information regarding the SPIRIT 2013  
204 items is detailed in references<sup>1,2</sup>. Table 1 lists the items of the SPIRIT 2013 checklist (left column) and



205 the SPIRIT-PRO extensions/elaborations (right-hand column). The 11 extensions and 5 elaborations  
206 incorporated 34 of the original 56 candidate items, as 27 items were merged by consensus. One new  
207 item was generated through discussion (SPIRIT-18a-PRO Extension (iii)). Definitions of key terms are  
208 contained in the Glossary (Box). Below we provide a brief explanation for each PRO  
209 extension/elaboration, including references to supporting empirical evidence where available (items  
210 6a through 22). Item 5a was not supported by empirical evidence but was supported by expert opinion  
211 drawn from our systematic review of PRO protocol guidance<sup>15</sup>, and in line with the development of the  
212 original SPIRIT statement<sup>1, 2</sup>, was underpinned by a strong pragmatic rationale.

213

#### 214 **Administrative Information**

##### 215 **Specify the individual(s) responsible for the PRO content of the trial protocol: SPIRIT-5a-PRO**

216 **Elaboration.** Explanation: Providing information (eg, name, affiliation, contact details) on who wrote  
217 the PRO specific aspects of the trial protocol promotes transparency and accountability, and identifies  
218 the appropriate point of contact for resolution of any PRO specific queries. Where patients have  
219 actively contributed to this process, this should be documented as per recent guidance for the  
220 reporting of patient and public involvement.<sup>17</sup>

221

##### 222 **Describe the PRO specific research question and rationale for PRO assessment, and**

223 **summarize PRO findings in relevant studies: SPIRIT-6a-PRO Extension.** Explanation: Inclusion of  
224 PROs in a trial requires careful consideration and planning. A clearly defined question helps with  
225 selection of measures and specification of hypotheses and analyses. Evidence suggests that many  
226 trials include PROs without specifying the PRO-specific research question, and without a rationale or  
227 any reference to PROs in related studies.<sup>7-9</sup> Consequently, staff and patients may not understand why  
228 PROs are being assessed, and missing data may result.<sup>7-12</sup> When the PRO is a secondary outcome,  
229 a brief rationale may be adequate.

230

##### 231 **State specific PRO objectives or hypotheses (including relevant PRO concepts/domains):**

232 **SPIRIT-7-PRO Extension.** Explanation: PRO measures may be multidimensional (eg, HRQOL) or  
233 unidimensional (eg, specific symptoms such as pain) and assessments may be scheduled at several  
234 time points during a trial. Pre-specification of objectives and hypotheses encourages identification of

235 key PRO domains and time-points, reducing the risk of multiple statistical testing and selective  
236 reporting of PROs based on statistically significant results (see also PRO elaboration 20a below).<sup>4</sup>

237

238 **Methods: Participants, interventions, and outcomes**

239 **Specify any PRO-specific eligibility criteria (eg, language/reading requirements or pre-**  
240 **randomization<sup>18</sup> completion of PRO). If PROs will not be collected in the entire study sample,**  
241 **provide a rationale and describe the method for obtaining the PRO subsample: SPIRIT-10-PRO**  
242 **Extension.** Explanation: Any PRO-specific eligibility criteria should be considered at the design stage  
243 of the trial and clearly specified in the protocol. In large trials, sufficient power may be achieved by  
244 collecting PROs from a representative subset of participants; whilst in some trials it may not be  
245 possible to collect PROs in the entire population (eg, due to non-availability of validated  
246 questionnaires in all languages)<sup>8</sup>; in such instances the rationale for the sampling method should be  
247 described.

248

249 **Specify the PRO concepts/domains used to evaluate the intervention (eg, overall HRQOL,**  
250 **specific domain, specific symptom) and, for each one, the analysis metric (eg, change from**  
251 **baseline, final value, time to event) and the principal time point or period of interest: SPIRIT-**  
252 **12-PRO Extension.** Explanation: The PRO concepts/domains and time points for assessment should  
253 closely align with the trial objectives and hypotheses. Because of the risk of multiple statistical testing,  
254 the domain(s) and principal time point(s) for analyses should be specified a priori.<sup>4,19</sup>

255

256 **Include a schedule of PRO assessments, providing a rationale for the time points, and**  
257 **justifying if the initial assessment is not pre-randomization. Specify: time windows; whether**  
258 **PRO collection is prior to clinical assessments; and if using multiple questionnaires, whether**  
259 **order of administration will be standardized: SPIRIT-13-PRO Extension.** Explanation: Provision of  
260 an easy to follow schedule will assist staff and may help reduce missing data.<sup>18</sup> Collecting PRO data  
261 prior to randomization helps ensure an unbiased baseline assessment, and if specified as an eligibility  
262 criterion, ensures data completeness. This is important as baseline PRO data are often used as a  
263 covariate in analyses and is essential to calculating change from baseline. Completion of PROs prior  
264 to clinical assessments (as these may influence patient responses) and standardization of the order of

265 questionnaire administration are advised to help reduce measurement error.<sup>20</sup> Allowable time  
266 windows for each scheduled PRO assessment should be specified to ensure that PRO data collection  
267 captures the impact of the clinical event(s) of interest.

268

269 **Where a PRO is the primary endpoint, state the required sample size (and how it was**  
270 **determined) and recruitment target (accounting for expected loss to follow-up). If sample size**  
271 **is not established based on PRO endpoint, then discuss the power of the principal PRO**  
272 **analyses: SPIRIT-14-PRO Elaboration.** Explanation: In studies in which PROs are the primary  
273 outcome/endpoint, the target sample size will generally be based on an a priori sample size  
274 calculation for that endpoint.<sup>19</sup> Ideally the criteria for clinical significance (eg, minimal important  
275 difference and/or responder definition) should be specified when known.<sup>21,22</sup> If PROs are the  
276 secondary endpoint, researchers should specify whether the sample size provides sufficient power to  
277 test the principal PRO hypotheses.<sup>19</sup>

278

279 **Methods: Data collection, management, and analysis**

280 **Justify the PRO instrument to be used, and describe domains, number of items, recall period,**  
281 **instrument scaling/scoring (eg, range and direction of scores indicating a good/poor**  
282 **outcome). Evidence of PRO instrument measurement properties, interpretation guidelines, and**  
283 **patient acceptability/burden should be provided or cited if available, ideally in the population**  
284 **of interest. State whether the measure will be used in accordance with any user manual and**  
285 **specify and justify deviations if planned: SPIRIT-18a(i)-PRO Extension.** Explanation: The  
286 selection of PROs to be used in a clinical trial requires careful consideration. Ideally the measure  
287 should be validated in the target population.<sup>23</sup> Consideration should be given to the number of  
288 questionnaires to be used, acceptability of the questions, and the likely patient burden (eg, time taken  
289 for completion and cognitive and/or emotional burden). Justification for the measures selected will  
290 help trial personnel understand why specific measures are being used.<sup>10</sup> Questionnaires should be  
291 used in accordance with any existing user manuals to promote data quality and ensure standardized  
292 scoring, and any deviations should be described.

293

294 **Include a data collection plan outlining the permitted mode(s) of administration (eg, paper,**  
295 **telephone, electronic, other) and setting (eg, clinic, home, other): SPIRIT-18a(ii)-PRO**

296 **Extension.** Explanation: It is important that both research personnel and trial participants understand  
297 how, when, and where PRO data will be collected in the study. Increasingly, electronic PRO  
298 assessment is undertaken in trials, so evidence of equivalence between different modes of  
299 administration should be considered.<sup>24</sup> If electronic PRO measures contain only minor modifications  
300 with respect to the paper based versions, usability testing and cognitive debriefing may provide  
301 sufficient evidence of equivalence.<sup>24,25</sup> The setting for PRO data collection should be described and  
302 standardized across trial arms and sites.

303

304 **Specify whether more than one language version will be used, and state whether translated**  
305 **versions have been developed using currently recommended methods: SPIRIT-18a(iii)-PRO**

306 **Extension.** Explanation: Multinational trials, or national trials involving participants with different  
307 languages, will require measures that have been translated, and culturally adapted where needed,  
308 using appropriate methodology.<sup>11,26</sup> This may influence the selection of measure to be used, since  
309 inclusivity of participants can help ensure the generalizability of trial results. Plans to use translated  
310 versions should be specified in the protocol, citing references where available.

311

312 **Where the trial context requires someone other than the trial participant to answer on their**  
313 **behalf (a proxy reported outcome), state and justify this. Provide/cite evidence of the validity**  
314 **of proxy assessment if available: SPIRIT-18a(iv)-PRO Extension.** Explanation: In some contexts,

315 eg, trials involving young children, or cognitively impaired participants, it may be necessary for  
316 someone other than the trial participant to respond on their behalf. Clear justification and specification  
317 of proxy reporting in the protocol will allow external reviewers to assess potential bias and will  
318 facilitate trial reporting in accordance with CONSORT-PRO.<sup>27</sup> Evidence of the size and direction of  
319 proxy bias is a key aspect of the validity of proxy versions of PRO measures, informing valid  
320 interpretation and comparison of results. Note that the European Medicines Agency (EMA) state that  
321 'in general proxy reporting should be avoided, unless the use of such proxy raters may be the only  
322 effective means of obtaining information that might otherwise be lost'.<sup>5</sup> The US Food and Drug

323 Administration (FDA) also discourages the use of proxy reported outcomes to inform labelling claims,  
324 recommending observer reports instead.<sup>4</sup>

325

326 **Specify PRO data collection and management strategies for minimising avoidable missing**  
327 **data: SPIRIT-18b(i)-PRO Extension.** Explanation: Missing data is a particular problem for PROs  
328 since it is often those participants with the poorest outcomes in a trial that fail to complete planned  
329 PRO assessments and data cannot be obtained retrospectively beyond the timeframe of interest or  
330 from medical records. This is a potentially significant source of bias, and may reduce trial power.<sup>28</sup> It is  
331 important to note that not all missing PRO data is avoidable: patients have the right to decide not to  
332 complete questionnaires. Common reasons for avoidable missing PRO data are administrative errors,  
333 lack of explanation of the importance of PRO data, and overly-burdensome questionnaires.  
334 Addressing these in the protocol should help minimize avoidable missing data. A recent systematic  
335 review provides a range of design, implementation and reporting strategies to help minimize and  
336 address missing PRO data.<sup>18</sup> Examples of protocol content include: ensuring PRO endpoints and  
337 hypotheses are clearly defined and scientifically compelling, providing a rationale for PRO  
338 assessment, clearly specifying the PRO assessment time points, defining acceptable PRO  
339 assessment time windows, aligning PRO assessment time points to clinic visits (if clinically  
340 informative), minimizing patient burden, and specifying the importance of complete PRO data.<sup>18</sup>

341

342 **Describe the process of PRO assessment for participants who discontinue or deviate from**  
343 **their assigned intervention protocol: SPIRIT-18b(ii)-PRO Elaboration.** Explanation: A clear plan  
344 for collection of PROs for trial participants who withdraw early from a study or who discontinue the  
345 intervention will help minimise bias,<sup>29</sup> ensure staff collect all required PRO data in a standardized and  
346 timely way, and may assist ethical appraisal of the study.

347

348 **State PRO analysis methods including any plans for addressing multiplicity/type 1 ( $\alpha$ ) error:**  
349 **SPIRIT-20a-PRO Elaboration.** Explanation: Many questionnaires, such as HRQOL measures, are  
350 multidimensional and therefore may yield several summary scores (eg, multiple domains and an  
351 overall score). Further, PROs are usually assessed at multiple time points. Statistical analysis of all  
352 domains and timepoints implies multiple hypothesis testing, which inflates the probability of false

353 positives (type 1 error, or 'alpha').<sup>19</sup> This can be contained by pre-specifying the key PRO domain(s)  
354 or overall score of interest, and the principal time point(s). Any plans to address multiplicity, such as  
355 step-wise or sequential analyses, whereby multiple endpoints are tested in a defined sequence that  
356 contains the overall type 1 error to the desired level, or conventional non-hierarchical methods (eg,  
357 Bonferroni correction), should be specified a priori.<sup>4</sup> The protocol should either fully address these  
358 issues, or provide a summary, with reference to where full details can be found (eg, in the statistical  
359 analysis plan (SAP)).

360

361 **State how missing data will be described and outline the methods for handling missing items**  
362 **or entire assessments (eg, approach to imputation and sensitivity analyses): SPIRIT-20c-PRO**

363 **Elaboration.** Explanation: There are two levels of missing PRO data: 1) patient completion of some,  
364 but not all items within an instrument; 2) absence of the entire PRO assessment. Whether and how  
365 missing items should be imputed is usually specified in an instrument's scoring algorithm. When entire  
366 PRO assessments are missed, analysis requires assumptions about why those data were missing (ie,  
367 the missing data mechanism). There are a range of statistical approaches, each with specific  
368 assumptions. Inappropriate method selection may lead to potentially biased and misleading  
369 results.<sup>18,29</sup> Common methods include complete case analysis, imputation (various approaches), a  
370 range of maximum likelihood modelling approaches, and sensitivity analysis.<sup>29</sup> The protocol should  
371 acknowledge these issues, and address them in summary, with full detail provided in the SAP.

372

373 **Methods: Monitoring**

374 **State whether or not PRO data will be monitored during the study to inform the clinical care of**  
375 **individual trial participants and, if so, how this will be managed in a standardized way.**

376 **Describe how this process will be explained to participants, eg, in the participant information**  
377 **sheet and consent form: SPIRIT-22-PRO Extension.** Explanation: Evidence suggests the

378 monitoring and management of 'PRO-alerts' (psychological distress or physical symptoms evident  
379 from PRO responses that may require an immediate response) varies across and within trials.<sup>10,11,30</sup>

380 In order to protect the interests of trial participants and minimize potential bias, it is important to

381 specify plans for monitoring.<sup>31</sup> If monitoring is not planned (for example in a low risk study where

382 alerts are not anticipated) then this should also be briefly stated in the protocol, the participant  
383 information sheet and consent form. Alternative support mechanisms for patients should be outlined.

384

### 385 **Supplementary trial documents**

386 Supplement 3 outlines additional items recommended for inclusion in other trial documentation such  
387 as the SAP, participant information sheet or in training/guidance documents for staff.

388

## 389 **DISCUSSION**

390 The SPIRIT-PRO Extension provides international consensus-based guidance on PRO-specific  
391 information that should be included in clinical trial protocols. It comprises 16 items: 5 elaborations to  
392 existing SPIRIT 2013 items in the context of PROs, and 11 new extensions, for use alongside the  
393 existing SPIRIT 2013 guidance.<sup>1,2</sup> It is important to note that these are minimum requirements, and  
394 that there may be value in including additional items in the protocol and/or in supplementary trial  
395 documents, as outlined in Supplement 3. While this guidance has been developed for trials where  
396 PROs are a primary or key secondary outcome we encourage protocol writers to consider use of this  
397 guidance in all trials or clinical research studies where PROs are collected, including if PROs are  
398 exploratory endpoints. The guidance does not aim to be prescriptive regarding how information  
399 should be included, as this may vary depending on the research setting and local requirements.  
400 Further details of empirical evidence underpinning the SPIRIT-PRO items and examples for  
401 implementation will be provided in a future explanatory publication on the PROlearn<sup>32</sup> and SPIRIT  
402 Initiative<sup>33</sup> websites and will be facilitated through further development of the SPIRIT 2013  
403 implementation tool SEPTRE<sup>33</sup> (SPIRIT Electronic Protocol Tool and Resource) and through  
404 dissemination via our international partners (see Supplement 1). Inclusion of PRO-specific protocol  
405 content will facilitate appraisal of the PRO elements by funders, reviewers, research ethics  
406 committees, and patient partners. The SPIRIT-PRO Extension is intended to encourage and facilitate  
407 careful planning of PRO components of trials, and thereby improve PRO trial design. Consequently,  
408 this is expected to help staff and patients understand the rationale for PRO assessment, improve  
409 PRO data completeness and quality, facilitate high quality analysis and reporting, and ultimately  
410 improve the quality of the global PRO evidence base.

411

412 To maximize the benefit of PRO data in policy and practice, it is recommended that careful  
413 consideration be given to the selection of outcomes and measures<sup>34,35</sup>, analysis of PRO data,<sup>4,5,36</sup> and  
414 transparent reporting in accordance with CONSORT-PRO.<sup>27</sup> Patient and public involvement in all of  
415 these aspects can help to ensure that PRO selection and application is transparent, relevant and  
416 acceptable.<sup>37-38</sup> Consistent with this philosophy, patient partners have been involved in all aspects of  
417 the development of the SPIRIT-PRO extension.<sup>37-38</sup> Ultimately, high quality PRO trial results will help  
418 ensure that the patient's voice is central to informing shared-decision making, labelling claims, clinical  
419 guidelines, and health policy, making patient-centered care a reality.

420

#### 421 **Limitations**

422 Respondents to the stakeholder survey were self-selecting and Delphi and consensus meeting  
423 participants were purposively sampled based on their roles and expertise relating to PROs.  
424 Participants are therefore more likely to have more knowledge relating to PROs than broader  
425 research personnel.

426

#### 427 **Conclusions**

428 The SPIRIT-PRO guidelines provide recommendations for items that should be addressed and  
429 included in clinical trial protocols in which PROs are a primary or key secondary outcome. Improved  
430 design of clinical trials including PROs could help ensure high-quality data that may inform patient-  
431 centered care.

432

433

434

435

436

437

438

439

440

441

442



443 **Article Information**

444 Corresponding author: Prof Melanie Calvert, Institute of Applied Health Research, Centre for Patient Reported  
445 Outcomes Research, University of Birmingham, Edgbaston, Birmingham, UK B15 2TT

446

447 Author Contributions: Profs Calvert and King had full access to all the data in the study and take responsibility for  
448 the integrity of the data and the accuracy of the data analysis. Prof Calvert and King co-chair the SPIRIT-PRO  
449 Group.

450

451 **The SPIRIT PRO Group**

452 Operations Group: Melanie Calvert, PhD, University of Birmingham, UK; Madeleine King, PhD, University of  
453 Sydney, Australia; Derek Kyte, PhD, University of Birmingham, UK; Rebecca Mercieca-Bebber, PhD, University  
454 of Sydney, Australia; Anita Slade, PhD, University of Birmingham, UK; Additional SPIRIT-PRO Group members  
455 and co-authors: Amanda Hunn, Health Research Authority (HRA), UK ; Andrew Bottomley, PhD, European  
456 Organization for Research and Treatment of Cancer (EORTC), Belgium; Antoine Regnault, PhD, Modus  
457 Outcomes, France; An-Wen Chan, MD, University of Toronto, Canada; Carolyn Ells, PhD, Panel on Research  
458 Ethics (On behalf of the: Canadian Institutes of Health Research, Natural Sciences and Engineering Research  
459 Council of Canada, and Social Sciences and Humanities Research Council of Canada),Canada; Daniel  
460 O'Connor, PhD, Medicines and Healthcare products Regulatory Agency (MHRA), UK; Dennis Revicki, PhD,  
461 Evidera, USA; Donald Patrick, PhD, University of Washington, USA; Doug Altman, DSc, University of Oxford, UK;  
462 Ethan Basch, MD, University of North Carolina, USA; Galina Velikova, PhD, University of Leeds, UK; Gary Price,  
463 Patient Partner, UK; Heather Draper, PhD, University of Warwick, UK; Jane Blazeby, MD, University of Bristol,  
464 UK; Jane Scott, PhD, Janssen Global Services, Johnson and Johnson, UK; Joanna Coast, PhD, University of  
465 Bristol, UK; Josephine Norquist, PhD, Merck Sharp & Dohme Corporation, USA; Julia Brown, MSc, University of  
466 Leeds, UK; Kirstie Haywood, PhD, University of Warwick, UK; Laura Lee Johnson, PhD, Food and Drug  
467 Administration (FDA), USA; Lisa Campbell, MD, Medicines and Healthcare products Regulatory Agency (MHRA),  
468 UK; Lori Frank, PhD, Patient-Centered Outcomes Research Institute (PCORI), USA; Maria von Hildebrand,  
469 Patient Partner, UK; Michael Brundage, MD, Queen's University, Canada; Michael Palmer, Queen's University  
470 MSc, Canada; Paul Kluetz, MD, Food and Drug Administration (FDA), USA; Richard Stephens, National Cancer  
471 Research Institute Consumer Forum, UK; Robert M Golub, MD, JAMA, USA; Sandra Mitchell, PhD, National  
472 Cancer Institute, USA; Trish Groves, MRCPsych, British Medical Journal (BMJ), UK.

473

474 Study concept and design: all authors

475 Statistical Analysis: Slade

476 Drafting of the manuscript: Calvert, Kyte, Mercieca-Bebber, Slade, Chan and King

477 Critical revision of the manuscript for important intellectual content: All authors.  
478 Obtained funding: Calvert (PI), Kyte, King, Altman, Blazeby, Brown, Brundage, Coast, Draper, von Hildebrand,  
479 Ives, Mercieca-Bebber, Price, Roberts, Slade  
480  
481 Study supervision: Calvert, Kyte, Mercieca-Bebber, Slade and King.  
482  
483 Administrative Support: Anita Walker, University of Birmingham, UK  
484  
485 **Conflict of Interest Disclosures:** All authors have completed and submitted the ICMJE Form for Disclosure of  
486 Potential Conflicts of Interest. Calvert, Kyte, King, Altman, Blazeby, Brown, Brundage, Coast, Draper, von  
487 Hildebrand, Mercieca-Bebber, Price, Roberts, Slade report a grant from Macmillan cancer support during the  
488 conduct of the study. Calvert and King co-chair the ISOQOL best practice for PROs in Trials PROtocol Taskforce  
489 and Calvert also reports personal fees from Astellas and grants from the National Institute for Health Research  
490 outside the submitted work. Velikova reports that she was past president of ISOQOL, past chair of EORTC  
491 Quality of Life Group and has received consultancy fees from Roche, Eisai and Novartis related to her clinical  
492 work in breast cancer, and grants from National Institute Health Research England, Yorkshire Cancer Research,  
493 Breast Cancer Now, EORTC Quality of Life Group, outside the submitted work. Scott participated in the SPIRIT-  
494 PRO Delphi panel and consensus meeting as part of her employment with Janssen-Cilag UK. She also holds  
495 Johnson & Johnson stock outside the submitted work. Golub reports stipends for teaching from Northwestern  
496 University Feinberg School of Medicine outside the submitted work. Kyte reports grants from the NIHR outside  
497 the submitted work. Travel and accommodation costs for consensus meeting participants were met by the  
498 University of Birmingham funded by the Macmillan Cancer Support Grant. No other disclosures were reported.  
499  
500 **Funding/Support:** This work was funded by Macmillan Cancer Support (grant number 5592105) and the  
501 University of Birmingham and was sponsored by the University of Birmingham. Professor King is supported by  
502 the Australian Government through Cancer Australia. JMB is partially supported by the MRC ConDuCT-II Hub for  
503 Trials Methodology Research. Professor Calvert, Dr Kyte and Dr Slade are funded by the NIHR Birmingham  
504 Biomedical Research Centre and the NIHR Surgical Reconstruction and Microbiology Research Centre. The  
505 views expressed in this publication are those of the authors and not necessarily those of the NHS, the National  
506 Institute for Health Research or the Department of Health.  
507  
508 **Role of the Funder/Sponsor:** The funder/sponsor did not have any involvement in the design and conduct of the  
509 study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the  
510 manuscript; and decision to submit the manuscript for publication

511

512 **Disclaimer:** Please note that views of authors, Delphi and stakeholder participants are individual views and may  
513 not represent the views of the broader stakeholder group or host institution. This work reflects the views of the  
514 author and should not be construed to represent the views or policies of the U.S. Food and Drug Administration.

515

516

517 **Additional Contributions:** The SPIRIT-PRO Group gratefully acknowledge the additional contributions made by  
518 the SPIRIT-PRO Executive, the ISOQOL Best Practices for PROs in Randomized Clinical Trials PROtocol  
519 Checklist Taskforce, the international stakeholders responsible for stakeholder survey distribution and  
520 stakeholders who completed the stakeholder survey, Delphi Panellists, the SPIRIT-PRO International  
521 Consensus Meeting Participants and Anita Walker, University of Birmingham, UK for administrative support as  
522 detailed in Supplement 1.

523

## **Glossary Box**

### **SPIRIT**

Standard Protocol Items: Recommendations for Interventional Trials<sup>1,2</sup>

### **SPIRIT-PRO Extension Item**

An additional checklist item describing PRO protocol content to address an aspect of PRO assessment that is not adequately covered by SPIRIT, as judged by available evidence and expert opinion.

### **SPIRIT Elaboration Item**

An elaboration of an existing SPIRIT item as applied to a specific context; in this instance, as applied to clinical trials assessing PROs.

### **Patient-Reported Outcome (PRO)**

An outcome reported directly by patients themselves and not interpreted by an observer; PROs may include patient assessments of health status, quality of life, or symptoms.<sup>27</sup>

### **Proxy-Reported Outcome**

'A measurement based on a report by someone other than the patient reporting as if he or she is the patient.'<sup>4</sup>

### **Health-Related Quality of Life (HRQOL)**

'HRQOL is a multidimensional concept that usually includes self-report of the way in which physical, emotional, social, or other domains of well-being are affected by a disease or its treatment.'<sup>27</sup>

### **Primary Outcome/ Endpoint**

The most important outcome in a trial, providing the most clinically relevant evidence directly related to the primary objective of the trial.

### **Secondary Outcomes / Endpoint(s)**

These are outcomes pre-specified in the protocol to assess additional effects of the intervention. Some PROs may be identified as important or key secondary outcomes.

### **'Important' or 'Key' Secondary Patient-Reported Outcomes / Endpoints**

Some PRO measures (particularly HRQOL measures) are multidimensional, producing several domain-specific outcome scales, e.g. pain, fatigue, physical function, psychological distress. For any particular trial, it is likely that a particular PRO or PRO domain(s) will be more relevant than others, reflecting the expected effect(s) of the trial intervention(s) in the target patient population. These relevant PRO(s) and/or domain(s) may additionally constitute the important or key secondary PROs (identified a priori and specified as such in the trial protocol and statistical analysis plan) and will be the focus of hypothesis testing. In a regulatory environment, these outcomes may support a labelling claim. Because these outcomes are linked with hypotheses (see CONSORT PRO Extension 2b)<sup>27</sup>, they may be subject to P value adjustment (or 'alpha-spending'). Note: PROs may not only provide evidence of efficacy/effectiveness but may also be intended to capture and provide evidence of safety and tolerability (e.g. PRO-CTCAE).<sup>39</sup>

### **Concept**

'The specific measurement goal (ie, the thing that is to be measured by a PRO instrument). In clinical trials, a PRO instrument can be used to measure the effect of a medical intervention on one or more concepts. PRO concepts represent aspects of how patients function or feel related to a health condition or its treatment.'<sup>4</sup>

### **Domain**

'A subconcept represented by a score of an instrument that measures a larger concept comprised of multiple domains. For example, psychological function is the larger concept containing the domains subdivided into items describing emotional function and cognitive function.'<sup>4</sup>

### **Instrument**

'A means to capture data (ie, a questionnaire) plus all the information and documentation that supports its use. Generally, that includes clearly defined methods and instructions for administration or responding, a standard format for data collection, and well-documented methods for scoring, analysis, and interpretation of results in the target patient population.'<sup>4</sup>

### **Item**

'An individual question, statement, or task (and its standardized response options) that is evaluated by the patient to address a particular concept.'<sup>4</sup>

### **Time window**

A pre-defined time frame before and after the protocol-specified PRO assessment time point whereby the result would still be deemed to be clinically relevant.<sup>40</sup>

## References

1. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. *Annals of Internal Medicine*. 2013;158(3):200-207.
2. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *British Medical Journal*. 2013;346:1-42.
3. Doward LC, Gnanasakthy A, Baker MG. Patient reported outcomes: looking beyond the label claim. *Health and Quality of Life Outcomes*. 2010;8(1):89.
4. U.S. Department of Health and Human Services Food and Drug Administration (FDA). Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Maryland, US: FDA; 2009.
5. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies EMA/CHMP/292464/2014. Canary Wharf, London: EMA; 2016
6. Tunis SR, Stryer DB, Clancy CM. Practical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in Clinical and Health Policy. *JAMA*. 2003;290(12):1624-1632.
7. Kyte D, Duffy H, Fletcher B, et al. Systematic Evaluation of the Patient-Reported Outcome (PRO) Content of Clinical Trial Protocols. *PLoS ONE* 2014;9(10): e110229.
8. Kyte D, Retzer A, Keeley T et al. Systematic evaluation of Patient-Reported Outcome (PRO) protocol content and reporting in cancer clinical trials: the EPIC study *Quality of Life Research*. 2017; 26:55.
9. Mercieca-Bebber R, Friedlander M, Kok P-S et al. The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. *Quality of Life Research*. 2016; 25:2457-2465.
10. Kyte D, Ives J, Draper H, Keeley T, Calvert M. Inconsistencies in quality of life data collection in clinical trials: a potential source of bias? Interviews with research nurses and trialists. *PLoS ONE*. 2013;8(10):e76625.
11. Mercieca-Bebber R, Calvert M, Kyte D, Stockler M, King MT. The administration of patient-reported outcome questionnaires in cancer trials: Interviews with trial coordinators regarding their roles, experiences, challenges and training. *Contemporary Clinical Trials Communications*. 2018;9(Supplement C):23-32.
12. Kyte D, Ives J, Draper H, Calvert M. Current practices in patient-reported outcome (PRO) data collection in clinical trials: a cross-sectional survey of UK trial staff and management. *BMJ Open*. 2016;6(10)
13. Calvert M, Kyte D, von Hildebrand M, King M, Moher D. Putting patients at the heart of health-care research *The Lancet*. 2015;385(9973):1073-1074.
14. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. *PLoS Medicine*. 2010;7(2):e1000217.
15. Calvert M, Kyte D, Duffy H, et al. Patient reported outcome (PRO) assessment in clinical trials: A systematic review of guidance for trial protocol writers. *PLoS ONE*. 2014;9(10):e110216.
16. Centre for Patient Reported Outcomes Research. International Consensus Guidance on the Inclusion of Patient-Reported Outcomes (PROs) in Clinical Trial Protocols: The SPIRIT-PRO Extension. 2017. <http://www.birmingham.ac.uk/research/activity/mds/centres/cpror/research/spirit-pro.aspx>. Accessed August 21, 2017.
17. Staniszewska S, Brett J, Simera I, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. *BMJ*. 2017;358:j3453
18. Mercieca-Bebber R, Palmer MJ, Brundage M, Calvert M, Stockler MR, King MT. Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review. *BMJ Open*. 2016;6(6).
19. Sloan JA, Dueck AC, Erickson PA, et al. Patient-Reported Outcomes Consensus Meeting Group Analysis and interpretation of results based on patient-reported outcomes. *Value in Health*. 2007;10(2):S106-115.
20. Leidy NK, Revicki DA, Genesté B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. *Value in Health*. 1999;2(2):113–127.
21. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. *Journal of Clinical Epidemiology* 2008;61(2): 102–109.
22. King MT. A point of minimal important difference (MID): a critique of terminology and methods. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2011;11(2):171–184.
23. Rothrock NE, Kaiser KA, Cella D. Developing a Valid Patient-Reported Outcome Measure. *Clinical pharmacology and therapeutics*. 2011;90(5):737-742.
24. Coons SJ, Gwaltney CJ, Hays RD, et al. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. *Value in Health*. 2009;12(4):419-429.
25. Rutherford C, Costa D, Mercieca-Bebber R, Rice H, Gabb L, King M. Mode of administration does not cause bias in patient-reported outcome results: a meta-analysis. *Quality of Life Research*. 2016;25(3):559-574.
26. Wild D, Grove A, Martin M, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. *Value in Health*. 2005;8(2):94–104.
27. Calvert M, Blazeby J, Altman DG, et al. Reporting of Patient-Reported Outcomes in Randomized Trials: The CONSORT-PRO Extension. *JAMA*. 2013;309(8):814-822.
28. Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. *Stat Med*. 1998;17(5-7):517-532.
29. Fairclough DL. *Design and Analysis of Quality of Life Studies in Clinical Trials*, 2nd edn. Boca Raton, Florida: Chapman & Hall/CRC. 2010
30. Kyte D, Ives J, Draper H, Calvert M. Management of Patient-Reported Outcome (PRO) Alerts in Clinical Trials: A Cross Sectional Survey. *PLoS ONE*. 2016;11(1):e0144658.
31. Kyte D, Draper H, Calvert M. Patient-reported outcome alerts: ethical and logistical considerations in clinical trials. *JAMA*. 2013;310(12):1229-1230.
32. PROlearn [www.birmingham.ac.uk/prolearn](http://www.birmingham.ac.uk/prolearn). Accessed June 23, 2017.
33. SPIRIT Initiative <http://www.spirit-statement.org>. Accessed June 23, 2017.
34. Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider. *Trials*. 2012;13:132.

35. Prinsen CA, Vohra S, Rose MR, et al. How to select outcome measurement instruments for outcomes included in a "Core Outcome Set" - a practical guideline. *Trials*. 2016;17(1):449.
36. Bottomley A, Pe M, Sloan J, et al. Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. *The Lancet Oncology*. 2016;17(11):e510-e514.
37. Haywood K, Lyddiatt A, Brace-McDonnell SJ, Staniszewska S, Salek S. Establishing the values for patient engagement (PE) in health-related quality of life (HRQoL) research: an international, multiple-stakeholder perspective. *Quality of Life Research*. 2017;26(6):1393-1404
38. Frank L, Basch E, Selby JV. The PCORI perspective on patient-centered outcomes research. *Patient-Centered Outcomes Research Institute*. *JAMA*. 2014;312(15):1513-1514.
39. Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Am Soc Clin Oncol Educ Book*. 2016;35:67-73.
40. Fayers PM, Hopwood P, Harvey A, Girling DJ, Machin D, Stephens R. Quality of life assessment in clinical trials--guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience. *MRC Cancer Trials Office*. *Eur J Cancer*. 1997;33(1):20-28.

**Table 1 SPIRIT 2013\* and SPIRIT-PRO Extension checklist: recommended items to address in a clinical trial protocol** \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” license and is reproduced by JAMA with their permission. #Indicates page numbers to be completed by authors during protocol development.

SPIRIT Section	SPIRIT Item No	SPIRIT Item Description	Addressed on page number#	SPIRIT-PRO Item No	SPIRIT PRO Extension Item Description	Addressed on page number#
<b>Administrative information</b>						
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym				
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry				
	2b	All items from the World Health Organization Trial Registration Data Set				
Protocol version	3	Date and version identifier				
Funding	4	Sources and types of financial, material, and other support				
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors		<b>SPIRIT-5a-PRO Elaboration</b>	Specify the individual(s) responsible for the PRO content of the trial protocol.	
	5b	Name and contact information for the trial sponsor				
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities				
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)				
<b>Introduction</b>						

Background and rationale	<b>6a</b>	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	<b>SPIRIT-6a-PRO Extension</b>	Describe the PRO specific research question and rationale for PRO assessment, and summarize PRO findings in relevant studies.
	<b>6b</b>	Explanation for choice of comparators		
Objectives	<b>7</b>	Specific objectives or hypotheses	<b>SPIRIT-7-PRO Extension</b>	State specific PRO objectives or hypotheses (including relevant PRO concepts/domains).
Trial design	<b>8</b>	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)		
<b>Methods: Participants, interventions, and outcomes</b>				
Study setting	<b>9</b>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained		
Eligibility criteria	<b>10</b>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	<b>SPIRIT-10-PRO Extension</b>	Specify any PRO-specific eligibility criteria (eg, language/reading requirements or pre-randomization completion of PRO). If PROs will not be collected in the entire study sample, provide a rationale and describe the method for obtaining the PRO subsample.
Interventions	<b>11a</b>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered		
	<b>11b</b>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)		
	<b>11c</b>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)		
	<b>11d</b>	Relevant concomitant care and interventions that are permitted or prohibited during the trial		
Outcomes	<b>12</b>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	<b>SPIRIT-12-PRO Extension</b>	Specify the PRO concepts/domains used to evaluate the intervention (eg, overall HRQOL, specific domain, specific symptom) and, for each one, the analysis metric (eg, change from baseline, final value, time to event) and the principal time point or period of interest.



Participant timeline	<b>13</b>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	<b>SPIRIT-13-PRO Extension</b>	Include a schedule of PRO assessments, providing a rationale for the time points, and justifying if the initial assessment is not pre-randomization. Specify: time windows; whether PRO collection is prior to clinical assessments; and if using multiple questionnaires, whether order of administration will be standardized.
Sample size	<b>14</b>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	<b>SPIRIT-14-PRO Elaboration</b>	Where a PRO is the primary endpoint, state the required sample size (and how it was determined) and recruitment target (accounting for expected loss to follow-up). If sample size is not established based on PRO endpoint, then discuss the power of the principal PRO analyses.
Recruitment	<b>15</b>	Strategies for achieving adequate participant enrolment to reach target sample size		
<b>Methods: Assignment of interventions (for controlled trials)</b>				
Allocation:				
Sequence generation	<b>16a</b>	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions		
Allocation concealment mechanism	<b>16b</b>	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned		
Implementation	<b>16c</b>	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions		
Blinding (masking)	<b>17a</b>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how		
	<b>17b</b>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial		
<b>Methods: Data collection, management, and analysis</b>				

Data collection methods	<b>18a</b>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	<b>SPIRIT-18a(i)-PRO Extension</b>	Justify the PRO instrument to be used, and describe domains, number of items, recall period, instrument scaling/scoring (eg, range and direction of scores indicating a good/poor outcome). Evidence of PRO instrument measurement properties, interpretation guidelines, and patient acceptability/burden should be provided or cited if available, ideally in the population of interest. State whether the measure will be used in accordance with any user manual and specify and justify deviations if planned.
			<b>SPIRIT-18a(ii)-PRO Extension</b>	Include a data collection plan outlining the permitted mode(s) of administration (eg, paper, telephone, electronic, other) and setting (eg, clinic, home, other).
			<b>SPIRIT-18a(iii)-PRO Extension</b>	Specify whether more than one language version will be used, and state whether translated versions have been developed using currently recommended methods.
			<b>SPIRIT-18a(iv)-PRO Extension</b>	Where the trial context requires someone other than the trial participant to answer on their behalf (a proxy reported outcome), state and justify this. Provide/cite evidence of the validity of proxy assessment if available.
Data management	<b>18b</b>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	<b>SPIRIT-18b(i)-PRO Extension</b>	Specify PRO data collection and management strategies for minimising avoidable missing data.
			<b>SPIRIT-18b(ii)-PRO Elaboration</b>	Describe the process of PRO assessment for participants who discontinue or deviate from their assigned intervention protocol.
Statistical methods	<b>19</b>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol		
Statistical methods	<b>20a</b>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<b>SPIRIT-20a-PRO Elaboration</b>	State PRO analysis methods including any plans for addressing multiplicity/type 1 ( $\alpha$ ) error.

	<b>20c</b>	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<b>SPIRIT-20c-PRO Elaboration</b>	State how missing data will be described and outline the methods for handling missing items or entire assessments (eg, approach to imputation and sensitivity analyses).
<b>Methods: Monitoring</b>				
	<b>21a</b>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed		
	<b>21b</b>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial		
Harms	<b>22</b>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<b>SPIRIT-22-PRO Extension</b>	State whether or not PRO data will be monitored during the study to inform the clinical care of individual trial participants and, if so, how this will be managed in a standardized way. Describe how this process will be explained to participants, eg, in the participant information sheet and consent form.
Auditing	<b>23</b>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor		
<b>Ethics and dissemination</b>				
Research ethics approval	<b>24</b>	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval		
Protocol amendments	<b>25</b>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)		
Consent or assent	<b>26a</b>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)		
	<b>26b</b>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable		
Confidentiality	<b>27</b>	How personal information about potential and enrolled participants will be collected, shared, and		

		maintained in order to protect confidentiality before, during, and after the trial
Declaration of interests	<b>28</b>	Financial and other competing interests for principal investigators for the overall trial and each study site
Access to data	<b>29</b>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
Ancillary and post-trial care	<b>30</b>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
Dissemination policy	<b>31a</b>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
	<b>31b</b>	Authorship eligibility guidelines and any intended use of professional writers
	<b>31c</b>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code
<b>Appendices</b>		
Informed consent materials	<b>32</b>	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	<b>33</b>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

1, 2, 33

